Profile data is unavailable for this security.
About the company
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
- Revenue in SEK (TTM)0.00
- Net income in SEK-241.07m
- Incorporated2009
- Employees23.00
- LocationCantargia ABScheelevagen 27LUND 223 63SwedenSWE
- Phone+46 462756260
- Websitehttps://cantargia.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Promimic AB | 39.53m | -9.38m | 602.63m | 17.00 | -- | 8.26 | -- | 15.24 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
Hamlet BioPharma AB | 0.00 | -26.59m | 626.05m | 7.00 | -- | 13.83 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
Gentian Diagnostics ASA | 142.65m | -5.85m | 662.08m | 58.00 | -- | 4.36 | 184.38 | 4.64 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
Oncopeptides AB | 39.17m | -245.79m | 675.28m | 62.00 | -- | -- | -- | 17.24 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
Orexo AB | 619.10m | -73.40m | 694.21m | 113.00 | -- | 11.22 | 119.69 | 1.12 | -2.13 | -2.13 | 17.98 | 1.78 | 0.6959 | 1.08 | 2.53 | 5,337,069.00 | -8.25 | -6.41 | -20.27 | -9.99 | 88.14 | 86.76 | -11.86 | -11.83 | 0.589 | 0.1386 | 0.8948 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
Moberg Pharma AB (publ) | 820.00k | -22.56m | 724.39m | 9.00 | -- | 1.18 | -- | 883.40 | -1.09 | -1.09 | 0.0379 | 21.63 | 0.0014 | -- | 0.2841 | -- | -3.81 | -- | -3.96 | -- | 60.00 | -- | -2,751.22 | -- | 1.73 | -- | 0.0073 | -- | -100.00 | -- | -34.26 | -- | -- | -- |
Intellego Technologies AB | 186.49m | 59.60m | 764.23m | 62.00 | 12.44 | 5.05 | 12.11 | 4.10 | 2.33 | 2.33 | 7.35 | 5.74 | 0.8841 | 3.87 | 3.69 | 3,007,968.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 2.07 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
Nightingale Health Oyj | 41.71m | -206.14m | 774.79m | 81.00 | -- | 1.16 | -- | 18.58 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
IRLAB Therapeutics AB | 5.68m | -157.30m | 807.90m | 28.00 | -- | 10.54 | -- | 142.29 | -3.03 | -3.03 | 0.1095 | 1.48 | 0.0274 | -- | 0.4652 | 218,384.60 | -75.97 | -27.12 | -94.23 | -30.42 | -1,952.47 | -72.18 | -2,770.38 | -155.57 | -- | -- | 0.2646 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
Alligator Bioscience AB | 55.49m | -248.80m | 817.17m | 55.00 | -- | -- | -- | 14.73 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
Cantargia AB | 0.00 | -241.07m | 881.70m | 23.00 | -- | 6.63 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7239 | 0.00 | -- | -- | 0.00 | -83.14 | -55.08 | -107.52 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
BioPorto A/S | 49.58m | -82.41m | 970.89m | 27.00 | -- | 15.20 | -- | 19.58 | -0.1501 | -0.1501 | 0.0903 | 0.1099 | 0.4132 | 3.66 | 7.33 | 1,044,452.00 | -68.68 | -71.10 | -100.20 | -96.55 | 68.08 | 63.38 | -166.23 | -239.22 | 2.36 | -- | 0.1354 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
Vistin Pharma ASA | 439.67m | 56.40m | 978.55m | 77.00 | 17.35 | 3.28 | 13.17 | 2.23 | 1.27 | 1.27 | 9.88 | 6.70 | 1.11 | 2.31 | 7.44 | 5,692,663.00 | 14.28 | 1.73 | 18.93 | 2.11 | 59.93 | 58.92 | 12.83 | 2.36 | 0.8536 | 32.96 | 0.0934 | -- | 51.35 | 16.95 | 1,066.84 | -- | -0.1922 | -- |
Diamyd Medical AB | 282.00k | -120.18m | 1.12bn | 26.00 | -- | 6.07 | -- | 3,976.10 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
SyntheticMR AB (publ) | 90.86m | 15.67m | 1.18bn | 38.00 | 74.39 | 9.82 | 53.38 | 12.99 | 0.3804 | 0.3804 | 2.21 | 2.88 | 0.6719 | -- | 1.58 | 2,455,541.00 | 11.59 | 7.19 | 13.87 | 8.85 | 73.94 | 69.70 | 17.25 | 9.08 | -- | -- | 0.0083 | 21.50 | 30.67 | 13.05 | 70.34 | -7.33 | 27.30 | -- |
Data as of May 31 2024. Currency figures normalised to Cantargia AB's reporting currency: Swedish Krona SEK
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 30 Jun 2023 | 14.74m | 8.03% |
F�rsta AP-fondenas of 30 Jun 2023 | 10.54m | 5.74% |
Alecta Pension Insurance Mutualas of 30 Jun 2023 | 10.10m | 5.50% |
Handelsbanken Fonder ABas of 30 Apr 2024 | 4.82m | 2.63% |
Swedbank Robur Fonder ABas of 29 Feb 2024 | 3.69m | 2.01% |
SEB Investment Management ABas of 30 Apr 2024 | 1.01m | 0.55% |
SSgA Funds Management, Inc.as of 09 May 2024 | 353.49k | 0.19% |
Alfred Berg Kapitalforvaltning ASas of 30 Jun 2023 | 160.18k | 0.09% |
Skandia Investment Management ABas of 28 Mar 2024 | 113.71k | 0.06% |
Storebrand Asset Management ASas of 31 Jan 2024 | 88.76k | 0.05% |
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.